Abstract Background ALK mutation occurs in approximately 3-5% of patients with NSCLC. At the baseline, Ple-I/E are more frequent in ALK+ patients with NSCLC. In the study, we aimed to… Click to show full abstract
Abstract Background ALK mutation occurs in approximately 3-5% of patients with NSCLC. At the baseline, Ple-I/E are more frequent in ALK+ patients with NSCLC. In the study, we aimed to evaluate characteristics of ALK+ patients who have Ple-I/E. Methods In this multicenter study, patients with ALK+ NSCLC who have Ple-I/E were retrospectively analyzed. Clinical and demographic characteristics of the disease, response rates, median PFS and OS were evaluated in 362 ALK+ patients with NSCLC. Results Of the patients, 198 (54.7%) were male. The median age at the time of diagnosis was 54 (21-85) years. The median age was higher in male (57 vs 52 years; p = 0.011). The most common histology was adenocarcinoma (100%). At the baseline, 57 (15.7%) patients had Ple-I/E. The median age of patients with Ple-I/E was similar to patients without Ple-I/E (53 vs 55 years; p = 0.541). The rate of smokers was 43.4% (n = 157) in the patients. There was no association between Ple-I/E and gender, lung metastasis and distant LAP metastasis. Pleural involvement was higher in non-smokers than smokers (19.4% vs 13.4%; p = 0.077), but not statistically significant. The frequencies of liver, brain and bone metastasis were a significant higher in ALK+ patients with Ple-I/E compared to those with non-metastatasis (respectively 18.2% vs 4.8%, p = 0.008; 19.1% vs 4.8%, p = 0.002; 20.6% vs 8.9%, p = 0.003). The median PFS was longer in ALK+ patients who have Ple-I/E 18.7 vs 10.6 months, p = 0.017). The 1-, 2- and 3-year PFS were 59%, 36%, and 24% in patients with Ple-I/E and 47%, 24%, and 8% in patients with non-involvement. Similarly, the median OS was longer in ALK+ patients who have pleural involvement/infusion 44.6 vs 22.6 months, p = 0.051). The 1-, 2- and 3-year OS were 78%, 67%, and 57% in patients with Ple-I/E and 66%, 48%, and 34% in patients with non-involvement. Conclusions Brain, liver and bone metastases are lower in ALK+patients with Ple-I/E. Presentation with Ple-I/E in patients with ALK+ NSCLC is associated with longer overall and progression-free survival. Legal entity responsible for the study The authors. Funding Has not received any funding. Disclosure All authors have declared no conflicts of interest.
               
Click one of the above tabs to view related content.